Choline autoradiography of human prostate cancer xenograft: Effect of castration

Molecular Imaging

Volumn 7, Issue 3, 2008, Pages 147-152

  Jadvar, Hossein ^a,b   Gurbuz, Alparslan ^a   Li, Xiankui ^a   Shahinian, Antranik ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPENDENTS; ATHYMIC; HUMAN PROSTATE CANCER CELLS; HUMAN PROSTATE CANCERS; HUMAN PROSTATES; MALE MOUSE; PROBABILITY LEVELS; TIME INTERVALS; TIME POINTS; TUMOR UPTAKES;

BIOLOGICAL MATERIALS; RADIOGRAPHY;

TUMORS;

ANDROGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ANIMAL; ARTICLE; AUTORADIOGRAPHY; CANCER TRANSPLANTATION; HUMAN; MALE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; RADIOISOTOPE DIAGNOSIS; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANDROGENS; ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHOLINE; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 61749094329     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2008.00018     Document Type: Article

References (31)

1. National Cancer Institute. SEER: The Surveillance, Epidemiology, and End Results program. Available at: http://seer.cancer.gov (Accessed April 28, 2008).
2. Sanz G, Rioja J, Zudaire JJ, et al. PET and prostate cancer. World J Urol 2004;22:351-2.
3. Hricak H, Choyke P, Eberhardt S, et al. Imaging prostate cancer: a multidisciplinary approach. Radiology 2007;243:28-53.
4. Lawrentschuk N, Davis ID, Bolton DM, et al. Positron emission tomography and molecular imaging of the prostate: an update. BJU Int 2006;97:923-31.
5. de Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18-23.
6. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40.
7. Reske SN, Blumstein NM, Neumaiet B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-54.
8. Martorana G, Schiavina R, Corti B, et al. 11C-Choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60.
9. Scher B, Seitz M, Albinger W, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53.
10. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007;100: 786-93.
11. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C] choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007;52:423-9.
12. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radica prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17.
13. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
14. Igerc L, Kohlfurst S, Gallowitsch HJ, Matschnig S, et al. The value of (18)F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging 2008. [Epub ahead of print].
15. Giovacchini G, Picchio M, Coradeschi E, et al. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008. [Epub ahead of print].
16. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004;31:859-65.
17. Jadvar H, Li X, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 2005;4: 91-7.
18. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32: 668-73.
19. Glunde K, Shah T, Winnard PT Jr, et al. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res 2008;68: 172-80.
20. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977-84.
21. Yoshida S, Nakagomi K, Goto S, et al. 11C-Choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 2005;74:214-20.
22. Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-5.
23. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/ CT with histopathologic step-section analysis. J Nucl Med 2005;46: 1642-9.
24. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-24.
25. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14.
26. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5 ng/mL? MoI Imaging Biol 2006;8:43-8.
27. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-7.
28. Price DT, Coleman RE, Liao RP, et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-80.
29. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262-9.
30. Zheng QH, Gardner TA, Raikwar S, et al. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 2004;12:2887-93.
31. Krause BJ, Souvatzpglou M, Tuncel M, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23.